The tumor microenvironment(TME)facilitates tumor development through intricate intercellular signaling,thereby supporting tumor growth and suppressing the immune response.Thyroid hormone receptor interactor 13(TRIP13)...The tumor microenvironment(TME)facilitates tumor development through intricate intercellular signaling,thereby supporting tumor growth and suppressing the immune response.Thyroid hormone receptor interactor 13(TRIP13),an AAA+ATPase,modulates the conformation of client macromolecules,consequently influencing cellular signaling pathways.TRIP13 has been implicated in processes such as proliferation,invasion,migration,and metastasis during tumor progression.Recent studies have revealed that TRIP13 also plays a role in immune response suppression within the TME.Thus,inhibiting these functions of TRIP13 could potentially enhance immune responses and improve the efficacy of immune checkpoint inhibition.This review summarizes the recent research progress of TRIP13 and discusses the potential of targeting TRIP13 to improve immune‐based therapies for patients with cancer.展开更多
基金Large Instruments Open Foundation of Nantong University,Grant/Award Number:KFJN2375National Natural Science Foundation of China,Grant/Award Number:82100557。
文摘The tumor microenvironment(TME)facilitates tumor development through intricate intercellular signaling,thereby supporting tumor growth and suppressing the immune response.Thyroid hormone receptor interactor 13(TRIP13),an AAA+ATPase,modulates the conformation of client macromolecules,consequently influencing cellular signaling pathways.TRIP13 has been implicated in processes such as proliferation,invasion,migration,and metastasis during tumor progression.Recent studies have revealed that TRIP13 also plays a role in immune response suppression within the TME.Thus,inhibiting these functions of TRIP13 could potentially enhance immune responses and improve the efficacy of immune checkpoint inhibition.This review summarizes the recent research progress of TRIP13 and discusses the potential of targeting TRIP13 to improve immune‐based therapies for patients with cancer.
